GALLI, MATTEO
 Distribuzione geografica
Continente #
NA - Nord America 191
AS - Asia 89
EU - Europa 83
SA - Sud America 33
AF - Africa 12
Totale 408
Nazione #
US - Stati Uniti d'America 188
SG - Singapore 69
IT - Italia 43
BR - Brasile 32
IE - Irlanda 16
CI - Costa d'Avorio 9
CN - Cina 6
DE - Germania 5
CZ - Repubblica Ceca 4
FI - Finlandia 4
IN - India 4
HK - Hong Kong 3
NL - Olanda 3
SN - Senegal 3
BD - Bangladesh 2
CA - Canada 2
CH - Svizzera 2
GB - Regno Unito 2
RU - Federazione Russa 2
EC - Ecuador 1
ES - Italia 1
IQ - Iraq 1
JO - Giordania 1
JP - Giappone 1
MX - Messico 1
SA - Arabia Saudita 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 408
Città #
Santa Clara 85
Singapore 60
Dublin 16
Chandler 14
Chicago 13
Rende 12
Abidjan 9
Civitanova Marche 6
New York 6
Reggio Emilia 6
Boardman 5
Cambridge 4
Lawrence 4
Andover 3
Boston 3
Brooklyn 3
Catania 3
Dakar 3
Hong Kong 3
Jacksonville 3
São Paulo 3
Tremestieri Etneo 3
Turku 3
Bastiglia 2
Columbus 2
Des Moines 2
Kochi 2
Nuremberg 2
Rome 2
San Francisco 2
Scarsdale 2
Alvorada 1
Amman 1
Arcoverde 1
Arraial do Cabo 1
Arroio Grande 1
Beijing 1
Belo Horizonte 1
Bernareggio 1
Boa Esperança 1
Bologna 1
Brasília 1
Bremen 1
Cajazeiras 1
Castanhal 1
Cranston 1
Curitiba 1
Dallas 1
Dhaka 1
Embu das Artes 1
Glasgow 1
Gravina di Catania 1
Guaratinguetá 1
Gustavo Adolfo Madero 1
Hebei 1
Helsinki 1
Ipirá 1
Itapetinga 1
Itapevi 1
Jeddah 1
Jiaxing 1
Joinville 1
João Pessoa 1
Macapá 1
Madre de Deus 1
Milan 1
Montreal 1
Moscow 1
Mosul 1
Munich 1
North Brunswick 1
Novo Hamburgo 1
Nueva Loja 1
Orlando 1
Palmdale 1
Philadelphia 1
Porto Alegre 1
Prague 1
Praia Grande 1
Redmond 1
Redwood City 1
Rimini 1
Rugby 1
Salvador 1
Santo André 1
Serra Talhada 1
Sete Lagoas 1
São Francisco do Sul 1
São João del Rei 1
The Dalles 1
Thāne 1
Tokyo 1
Toronto 1
Trento 1
Vitória 1
Wilmington 1
Zurich 1
Totale 352
Nome #
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 77
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 56
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 51
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 35
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 33
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis 33
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial 27
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 24
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 21
Weight gain: A possible side effect of all antiretrovirals 20
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 17
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 15
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 7
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 7
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 6
Totale 429
Categoria #
all - tutte 2.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.080


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 1 0 1 0 6 0 3 0 1 0
2021/202218 1 3 0 0 3 0 3 1 1 0 0 6
2022/202351 4 2 2 5 5 7 0 8 14 0 1 3
2023/202422 1 8 1 0 0 3 0 1 0 0 8 0
2024/2025295 0 22 9 7 98 43 9 5 18 28 34 22
2025/202626 26 0 0 0 0 0 0 0 0 0 0 0
Totale 429